Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
9.23
-0.18 (-1.91%)
At close: Aug 20, 2026, 4:00 PM EDT
9.24
+0.01 (0.11%)
After-hours: Aug 20, 2026, 4:53 PM EDT
Xilio Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 136.04 | 137.53 | 55.29 | 44.7 | 120.39 | 198.05 |
Cash & Short-Term Investments | 136.04 | 137.53 | 55.29 | 44.7 | 120.39 | 198.05 |
Cash Growth | 11.92% | 148.74% | 23.68% | -62.87% | -39.22% | 929.49% |
Receivables | 6 | 5 | - | - | - | - |
Prepaid Expenses | 3.43 | 2.5 | 4.94 | 3.42 | 4.11 | 4.46 |
Total Current Assets | 145.47 | 145.03 | 60.23 | 48.13 | 124.5 | 202.52 |
Property, Plant & Equipment | 6.97 | 7.85 | 9.06 | 11.2 | 13.06 | 13.9 |
Other Long-Term Assets | 1.82 | 1.81 | 1.78 | 1.6 | 1.61 | 1.64 |
Total Assets | 154.25 | 154.69 | 71.08 | 60.93 | 139.17 | 218.06 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2.32 | 3.17 | 2.57 | 1.05 | 3.13 | 3.14 |
Accrued Expenses | 7.85 | 11.74 | 9.98 | 10.5 | 10.33 | 8.75 |
Current Portion of Long-Term Debt | - | - | - | 3.32 | 6.67 | - |
Current Portion of Leases | 1.43 | 1.34 | 1.19 | 1.1 | 1 | 0.88 |
Current Unearned Revenue | 22.6 | 40.02 | 13.52 | - | - | - |
Total Current Liabilities | 34.2 | 56.27 | 27.26 | 15.96 | 21.12 | 12.78 |
Long-Term Debt | - | - | - | - | 3.17 | 9.63 |
Long-Term Leases | 4.88 | 5.61 | 6.95 | 8.14 | 9.23 | 10.23 |
Long-Term Unearned Revenue | 12.72 | 20.64 | 19.26 | - | - | - |
Other Long-Term Liabilities | 30.2 | 36.89 | - | - | - | - |
Total Liabilities | 81.99 | 119.41 | 53.48 | 24.1 | 33.52 | 32.63 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | - | - | 0 | 0 | 0 |
Additional Paid-In Capital | 506.95 | 454.06 | 401.35 | 362.34 | 354.75 | 346.31 |
Retained Earnings | -434.69 | -418.79 | -383.75 | -325.51 | -249.11 | -160.89 |
Total Common Equity | 72.26 | 35.27 | 17.6 | 36.83 | 105.65 | 185.43 |
Shareholders' Equity | 72.26 | 35.27 | 17.6 | 36.83 | 105.65 | 185.43 |
Total Liabilities & Equity | 154.25 | 154.69 | 71.08 | 60.93 | 139.17 | 218.06 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 6.3 | 6.95 | 8.14 | 12.55 | 20.07 | 20.74 |
Net Cash (Debt) | 129.74 | 130.58 | 47.15 | 32.15 | 100.32 | 177.32 |
Net Cash Growth | 13.82% | 176.94% | 46.64% | -67.95% | -43.42% | - |
Net Cash Per Share | 19.72 | 28.82 | 12.34 | 16.37 | 51.27 | 442.79 |
Filing Date Shares Outstanding | 6.58 | 5.78 | 3.7 | 2.46 | 1.96 | 1.95 |
Total Common Shares Outstanding | 6.58 | 4.53 | 3.27 | 1.97 | 1.96 | 1.95 |
Working Capital | 111.27 | 88.75 | 32.97 | 32.17 | 103.38 | 189.74 |
Book Value Per Share | 10.98 | 7.79 | 5.38 | 18.68 | 53.93 | 94.89 |
Tangible Book Value | 72.26 | 35.27 | 17.6 | 36.83 | 105.65 | 185.43 |
Tangible Book Value Per Share | 10.98 | 7.79 | 5.38 | 18.68 | 53.93 | 94.89 |
Machinery | 7.64 | 7.06 | 6.78 | 6.68 | 6.45 | 4.67 |
Construction In Progress | - | 0.46 | - | - | 0.1 | 0.54 |
Leasehold Improvements | 5.12 | 5.12 | 5.12 | 5.12 | 5.12 | 5.12 |